Alk-Abelló A/S

🇩🇰Denmark
Ownership
-
Established
1923-01-01
Employees
-
Market Cap
$5.8B
Website
http://www.alk.net/
Clinical Trials
Related News

Comparison of Different Up-dosing Schedules With Osiris

First Posted Date
2010-11-15
Last Posted Date
2011-08-29
Lead Sponsor
ALK-Abelló A/S
Target Recruit Count
210
Registration Number
NCT01240954

Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch

Phase 2
Completed
Conditions
Allergy
Interventions
Biological: oral immunotherapy
First Posted Date
2010-08-30
Last Posted Date
2013-02-08
Lead Sponsor
ALK-Abelló A/S
Target Recruit Count
66
Registration Number
NCT01191359
Locations
🇩🇪

Universitätsklinik Bonn, Dermatology, Bonn, Germany

Grazax Asthma Prevention

Phase 3
Completed
Conditions
Allergic Rhinitis
Interventions
Drug: Placebo
Drug: Grazax
First Posted Date
2010-02-03
Last Posted Date
2016-09-08
Lead Sponsor
ALK-Abelló A/S
Target Recruit Count
812
Registration Number
NCT01061203
Locations
🇫🇮

Terveystalo Turku, Turku, Finland

Exposure Chamber Trial With Cat Immunotherapy

First Posted Date
2009-10-01
Last Posted Date
2010-08-18
Lead Sponsor
ALK-Abelló A/S
Target Recruit Count
60
Registration Number
NCT00987909
Locations
🇨🇦

Cetero Research, Mississauga, Ontario, Canada

Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

First Posted Date
2009-09-16
Last Posted Date
2017-03-03
Lead Sponsor
ALK-Abelló A/S
Target Recruit Count
203
Registration Number
NCT00978029

Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients

First Posted Date
2009-03-09
Last Posted Date
2013-02-08
Lead Sponsor
ALK-Abelló A/S
Target Recruit Count
473
Registration Number
NCT00857779
Locations
🇩🇪

Allergists' practice Dr. Kirsten Jung, Erfurt, Thueringen, Germany

Intraseasonal Short-time Up-dosing With Alutard SQ Grasses

Phase 3
Completed
Conditions
Allergy
Interventions
Biological: Allergy vaccination (Alutard SQ)
First Posted Date
2008-12-12
Last Posted Date
2015-12-29
Lead Sponsor
ALK-Abelló A/S
Target Recruit Count
149
Registration Number
NCT00807547
Locations
🇩🇪

Center for Rhinology and Allergology, Wiesbaden, Germany

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)

First Posted Date
2008-10-31
Last Posted Date
2017-03-03
Lead Sponsor
ALK-Abelló A/S
Target Recruit Count
565
Registration Number
NCT00783198

A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment

Phase 3
Completed
Conditions
Grass Pollen Allergy
Interventions
Drug: Grazax
Drug: placebo
First Posted Date
2008-10-16
Last Posted Date
2011-08-30
Lead Sponsor
ALK-Abelló A/S
Target Recruit Count
276
Registration Number
NCT00773240
Locations
🇩🇰

ALK-Abello A/S, Bøge alle 6-8, Hørsholm, Denmark

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)

First Posted Date
2008-10-10
Last Posted Date
2017-03-03
Lead Sponsor
ALK-Abelló A/S
Target Recruit Count
784
Registration Number
NCT00770315
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy